PMID- 8145530
OWN - NLM
STAT- MEDLINE
DCOM- 19940505
LR  - 20220408
IS  - 0023-6837 (Print)
IS  - 0023-6837 (Linking)
VI  - 70
IP  - 3
DP  - 1994 Mar
TI  - A mouse model for studies of mucosal immunity to vaginal infection by herpes 
      simplex virus type 2.
PG  - 369-80
AB  - BACKGROUND: The role of mucosal immunity in defense of the female genital tract 
      against pathogens such as herpes simplex virus-2 (HSV-2) is poorly understood. 
      Here we explored the use of a new mouse model to determine whether local immune 
      events in the vagina of immune animals may protect them against genital herpes. 
      EXPERIMENTAL DESIGN: The effect of the estrous cycle, pregnancy, and sex hormones 
      on vaginal infection of adult mice by HSV-2 was determined by immunolabeling of 
      virus proteins. The immune response to infection was studied by immunolabeling of 
      T lymphocytes, B lymphocytes, and plasma cells in the vagina of infected mice. 
      RESULTS: Inoculation of attenuated virus (TK-HSV-2) or wild-type virus (TK+HSV-2) 
      into the vagina on day 6 of pregnancy or after treatment with Depo-Provera (DP) 
      caused infection of the vaginal epithelium. In contrast, these viruses did not 
      cause infection after vaginal inoculation at estrus, metestrus, or after 
      treatment with Depo-Estradiol. Infected mice showed immunolabeling of virus in 
      the vaginal epithelium from 24 hrs to 5 days after virus inoculation. The immune 
      response to infection included upregulation of class II MHC antigen in vaginal 
      epithelium, CD8+ T cells in epithelium and stroma, and plasma cells and lymphoid 
      nodules in the stroma. Mice that were infected with TK-HSV-2 did not exhibit 
      infection of vaginal epithelium when challenged 6 weeks later with TK+HSV-2. 
      CONCLUSIONS: Progesterone-dominated adult mice become infected after intravaginal 
      inoculation with HSV-2, but estradiol-dominated mice are refractory. Vaginal 
      infection with attenuated HSV-2 produces immunity that protects mice against 
      later infection by wild-type virus. This immunity either prevents infection of 
      vaginal epithelium or severely inhibits viral replication in the epithelium. The 
      observations suggest that the E/DP-treated adult mouse should be a useful model 
      for studies of mucosal immunity to vaginal infection by HSV-2.
FAU - Parr, M B
AU  - Parr MB
AD  - Southern Illinois University, Carbondale.
FAU - Kepple, L
AU  - Kepple L
FAU - McDermott, M R
AU  - McDermott MR
FAU - Drew, M D
AU  - Drew MD
FAU - Bozzola, J J
AU  - Bozzola JJ
FAU - Parr, E L
AU  - Parr EL
LA  - eng
GR  - HD-17737/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Lab Invest
JT  - Laboratory investigation; a journal of technical methods and pathology
JID - 0376617
RN  - 4TI98Z838E (Estradiol)
RN  - C2QI4IOI2G (Medroxyprogesterone Acetate)
SB  - IM
MH  - Animals
MH  - B-Lymphocytes/immunology
MH  - *Disease Models, Animal
MH  - Estradiol/pharmacology
MH  - Estrus/immunology
MH  - Female
MH  - Herpes Genitalis/*immunology
MH  - Herpesvirus 2, Human/*immunology
MH  - Immunity/drug effects
MH  - Medroxyprogesterone Acetate/pharmacology
MH  - Mice
MH  - *Mice, Inbred BALB C
MH  - Mucous Membrane/immunology
MH  - Plasma Cells/immunology
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/immunology
MH  - T-Lymphocytes/immunology
MH  - Vagina/*immunology
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
PST - ppublish
SO  - Lab Invest. 1994 Mar;70(3):369-80.